Allergan (NYSE:AGN) and its nonprofit partner, Medicines360, touted five-year data today from an on-going pivotal trial of its intrauterine device, Liletta. The levonorgestrel-releasing contraceptive is approved in the U.S. to be used to prevent pregnancy for up to four years. Get the full story at our sister site, Drug Delivery Business News.
Clinical Trials
Gilead inks $90m deal with Verily to create “molecular map” of inflammatory disease
Gilead Sciences (NSDQ:GILD) is reportedly slated to pay Alphabet’s Verily Life Sciences $90 million over three years to analyze cells from patients with rheumatoid arthritis, inflammatory bowel disease and lupus-related diseases. By probing immune cells from patients involved in Gilead’s clinical trials, the companies hope to glean a better understanding of the immunological signatures of RA, IBD and […]
Sight Sciences launches pivotal trial of TearCare dry-eye disease treatment
Ophthalmic medical device company Sight Sciences today announced the launch of a new pivotal trial exploring the safety and effectiveness of its TearCare system in patients with dry eye disease. The Menlo Park, Calif.-based company’s TearCare system is a wearable therapeutic eyelid technology designed to deliver energy over a specified period to liquify meibum, an oily coating […]
Inari Medical touts FlowTriever pulmonary embolism study data
Inari Medical today presented results from a study of its FlowTriever retrieval and aspiration system designed to treat pulmonary embolism, touting the safety and efficacy of the system. Results were presented by Dr. Thomas Tu of Louisville, Ky.’s Baptist Health in San Diego at the Scientific Sessions of the Society for Cardiovascular Angiography and Interventions, […]
Terumo Aortic launches feasibility study of RelayBranch thoracic stent-graft
Terumo Aortic, which formed earlier this month from a merger between Terumo Corp. (TYO:4543) subsidiary Vascutek and Bolton Medical, said today it launched an early feasibility study of its RelayBranch thoracic stent-graft system. The Sunrise, Fla.-based company said that the first two patients in the study have been implanted with the device by Dr. Luis Sanchez and […]
Flexion touts interim data from Ph3 trial of osteoarthritis injection
Flexion Therapeutics (NSDQ:FLXN) this week touted updated, interim results from an ongoing Phase IIIb study evaluating the safety and tolerability of repeat administration of its osteoarthritis injection, Zilretta. The company’s injectable suspension is an extended-release formulation of triamcinolone acetonide designed for patients with osteoarthritis of the knee. Top-line results from Flexion’s trial showed that 95% of […]
Post-approval registry shows positive 1-year results for Abbott’s MitraClip
A post-approval registry study of the MitraClip mitral valve repair device from Abbott (NYSE:ABT) showed positive results at one year, according to late-breaking results presented this week at the annual meeting of the Society for Cardiovascular Angiography & Interventions in San Diego. The real-world study, of the first 2,000 MitraClip patients treated in the Transcatheter Valve […]
Medtronic touts two-year Harmony transcath pulmonary valve feasibility study data
Medtronic (NYSE:MDT) today released two-year outcomes from an early feasibility study of its Harmony transcatheter pulmonary valve, touting solid valve function no reports of paravalvular leaks. Results were presented at the Society for Cardiovascular Angiography and Interventions 41st annual scientific sessions, the Fridley, Minn.-based company said. “Following the one-year feasibility outcomes, we are encouraged to see […]
Boston Scientific touts 1-year data on Vercise DBS in Parkinson’s
Boston Scientific (NYSE:BSX) today released one-year data from a study of its Vercise deep-brain stimulation device in treating Parkinson’s disease. Vercise, which is based on cochlear implant technology, is designed to stimulate a targeted region of the brain via independently controlled leads. The 292-patient Intrepid trial of subjects with advanced, levodopa-responsive Parkinson’s is a double-blind, sham-controlled study with a […]
Medtronic extends afib clinical trial support agreement with Arca Biopharma
Arca Biopharma said today it extended a US, Canadian and European clinical trial collaboration deal with medtech giant Medtronic (NYSE:MDT) for an additional year, now slated to continue until April 2019. Through the deal, Medtronic will support clinical trial use of its monitoring devices, collection of managed atrial fibrillation burden data and managed analysis of cardiac rhythms […]
FDA approves Medtronic’s drug-coated balloon to treat long superficial femoral artery lesions
The FDA approved Medtronic‘s (NYSE:MDT) In.Pact Admiral drug-coated balloon to treat long superficial femoral artery lesions up to 360mm in patients with peripheral artery disease, the medtech giant touted today. In a 227-patient global trial, participants treated with Medtronic’s drug-device combination therapy had a one-year patency rate of 89.1% and a clinically-driven target revascularization rate […]